Background: The induction of donor-specific immunological tolerance could improve outcome after kidney transplantation. However, no tolerance protocol is available for routine clinical use. Chimerism-based regimens hold promise, but their widespread application is impeded in part by unresolved safety issues. This study tests the hypothesis that therapy with polyclonal recipient regulatory T cells (Tregs) and anti-IL6R (tocilizumab) leads to transient chimerism and achieves pro-tolerogenic immunomodulation in kidney transplant recipients also receiving donor bone marrow (BM) without myelosuppressive conditioning of the recipient.Methods/design: A prospective, open-label, controlled, single-center, phase I/IIa academic study is performed in HLA-mismatched living donor kidney transplant recipients.Study group: Recipients of the study group receive in vitro expanded recipient Tregs and a donor bone marrow cell infusion within 3 days after transplantation and tocilizumab for the first 3 weeks post-transplant. In addition they are treated with thymoglobulin, belatacept, sirolimus, and steroids as immunosuppression. Starting 6 months post-transplant, sirolimus and steroids are withdrawn in a step-wise manner in stable patients.Control group: Recipients of the control group are treated with thymoglobulin, belatacept, sirolimus, and steroids as immunosuppression. Co-primary endpoints of safety (impaired graft function [eGFR <35 mL/min/1.73 m2], graft-vs.-host disease or patient death by 12 months) and efficacy (total leukocyte donor chimerism within 28 days post-transplant) are assessed. Secondary endpoints include frequency of biopsy-proven acute rejection episodes and subclinical rejection episodes on surveillance biopsies, assessment of kidney graft function, and the evaluation whether the study protocol leads to detectable changes in the immune system indicative of pro-tolerogenic immune modulation.Discussion: The results of this trial will provide evidence whether treatment with recipient Tregs and donor BM is feasible, safe and efficacious in leading to transient chimerism. If successful, this combination cell therapy has the potential to become a novel treatment option for immunomodulation in organ transplantation without the toxicities associated with myelosuppressive recipient conditioning.Trial registration: European Clinical Trials Database EudraCT Nr 2018-003142-16 and clinicaltrials.gov NCT03867617.
1 November 2020 in Journal of Investigative Dermatology
BACKGROUND: Ex vivo expansion of progentior cells may shorten hematopoietic regeneration after myeloablative chemoradiotherapy, increase target cells for gene therapy, and improve purging of progenitor cell components. STUDY DESIGN AND METHODS: Marrow cells were incubated for 1 week in suspension culture with and without IL‐10, IL‐3, and SCF. As long‐term culture initiating cells (LTC‐ICs) represent early hematopoietic progenitors in vitro, these cells were quantified at initiation and after a 1‐week culture period in a limiting dilution assays. Additionally, immunophenotyping of cells before and after culture was performed. RESULTS: In six experiments, marrow cells cultured for 1 week with IL‐10, IL‐3, and SCF showed a significant increase (almost doubling) in LTC‐ICs as compared with marrow cells before expansion. Additionally, an increased proliferative capacity of LTC‐ICs was achieved with a sevenfold increase of committed colony‐forming cells and a 10‐fold proliferation of high proliferative potential colony‐forming cells. Immunophenotyping revealed a sevenfold increase of CD34+ CD45 RA– cells in IL‐10‐, IL‐3‐, SCF‐stimulated suspension cultures. In unstimulated cultures, no LTC‐ICs were maintained after 1 week. CONCLUSION: Expansion of LTC‐ICs by IL‐10, IL‐3, and SCF has not been shown so far. This in vitro model allows expansion of LTC‐IC if compared with the input of progenitor cells without extensive progenitor cell manipulation. This should be an attractive model for in vitro purging, gene transfer, or expansion of progenitor cells to allow rapid engraftment after myeloablative chemotherapy.
Einleitung: Die gastrointestinale graft versus host disease (GvHD) ist eine häufige, mit hoher Morbidität und Mortalität assoziierte Komplikation nach Knochenmarkstransplantation (KMT). Die Diagnostik erfolgt üblicherweise gastroskopisch, Daten aus einer Kapselendoskopiestudie lassen den Schluss zu, dass das punctum maximum der Erkrankung im Dünndarm zu liegen scheint. Allerdings lässt diese Methode keine Entnahme von Gewebsproben zu. Aus diesem Grunde führten wir prospektiv bei Patienten mit Verdacht auf eine gastrotintestinale GvHD eine Push-Enteroskopie durch. Methodik: Eingeschlossen wurden Patienten nach allogener KMT mit gastrointestinalen Symptomen wie Übelkeit, Erbrechen und Diarrhoe nach Ausschluss von viralen und bakteriellen Infektionen oder medikamentösen Nebenwirkungen. Insgesamt wurden bei 24 konsekutiven Patienten 33 Push Enteroskopien durchgeführt (Olympus SIF-Q140) und Stufenbiopsien aus dem Jejunum, Duodenum sowie Magen entnommen. Ergebnisse: In insgesamt 14 Fällen konnte eine GvHD diagnostiziert werden. In 13 Fällen (92,9%) ließ sich die Erkrankung im Jejunum nachweisen, in 12 Fällen (78,6%, p=n.s.) im Duodenum und lediglich in 5 Fällen (35,7%, p=0,05) im Magen. In zwei Fällen (14,3%) fanden sich Veränderungen im Sinne einer GvHD nur im Jejunum, in einem Fall nur im Duodenum und Magen. Zusammenfassung: Die Entnahme von Biopsien aus dem Dünndarm bei Verdacht auf GvHD liefert signifikant mehr positive Befunde als Biopsien aus dem Magen. In zwei Fällen zeigten sich nur im Jejunum Veränderungen im Sinne einer graft versus host disease, die im Rahmen einer herkömmlichen Gastroduodenoskopie nicht diagnostiziert hätten werden können. Der Einsatz der Enteroskopie erscheint durch die höhere diagnostische Ausbeute im Vergleich zur Gastroskopie gerechtfertigt.